Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02775370
Other study ID # 2016HNRT003
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date May 2016
Est. completion date December 2018

Study information

Verified date September 2018
Source Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a non-randomized, phase II, open label study of Apatinib Mesylate in patients with Head and neck recurrent/metastatic adenoid cystic carcinoma (ACC). The primary purpose of this study is to evaluate the efficacy and safety of Apatinib Mesylate in patients with ACC.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 68
Est. completion date December 2018
Est. primary completion date December 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Histologically or cytologically confirmed adenoid cystic carcinoma

2. Recurrent/Metastatic disease documented as having shown progression on a scan (CT, MRI) compared to a previous scan taken at any time in the past. Progression must be documented according to RECIST criteria.

3. Presence of at least one measurable target lesion for further evaluation according to RECIST criteria

4. Disease that is not amenable to surgery, radiation or combined modality therapy with curative intent and was previously treated with chemotherapy

5. 18 years or older

6. Karnofsky score over 60

7. Previous treatment with chemotherapy, targeted agents, loco-regional therapy (e.g. chemoembolization) are permitted providing that toxicity has resolved to < or = grade 1 at study entry and that last treatment was at least 4 weeks prior to baseline assessment.

8. Adequate organ function

9. A patient with the willingness to comply with the study protocol during the study period and capable of complying with it

10. A patient who signed the informed consent prior to the participation of the study and who understands that he or she has a right to withdrawal from participation in the study at any time without any disadvantages.

Exclusion Criteria:

1. A patient with no measurable disease

2. Prior chemotherapy, radiation therapy or surgery within 4 weeks prior to study entry except palliative radiotherapy to non-target lesions (within 2 weeks prior to study entry)

3. A patient with previous active or passive immunotherapy

4. A patient with intestinal obstruction or impending obstruction, recent active upper GI bleeding

5. A pregnant or lactating patient

6. A patient of childbearing potential without being tested for pregnancy at baseline or with being tested for positive. (A postmenopausal woman with the amenorrhea period of at least 12 months or longer is considered to have non-childbearing potential)

7. A man or woman of childbearing potential who has no willingness to use a contraceptive measure during the study

8. A patient with history of another malignant disease within past 5 years, except curatively treated basal cell carcinoma of skin and cervical carcinoma in situ.

9. A patient with history of uncontrolled seizures, central nervous system disorder or psychiatric disorders that are considered clinically significant by the investigator that would prohibit the understanding of informed consent or that may be considered to interfere with the compliance of the administration of the study medications.

10. A patient with clinically significant heart disease (e.g. congestive heart failure, symptomatic coronary artery diseases, cardiac arrhythmia, etc) or myocardial infarction within past 12 months.

11. Ongoing cardiac arrhythmia of grade > or = 2, atrial fibrillation of any grade, or QTc interval > 450 msec for males or > 470 msec for female.

12. A patient with interstitial pneumonia or diffuse symptomatic fibrosis of the lungs

13. A patient with organ transplantation requiring immunosuppressive therapy

Study Design


Intervention

Drug:
Apatinib Mesylate
Apatinib Mesylate will be administered orally at 500 mg once daily for 5 consecutive days, and this was followed by a 2-day rest every week; each cycle consisted of 28 days

Locations

Country Name City State
China Shanghai ninth people's hospital Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival(PFS) To determine 6 month PFS of Apatinib Mesylate when administered as monotherapy in patients with metastatic adenoid cystic carcinoma 6 months
Secondary Overall survival rate from date of enrollment until date of first death from any cause, assessed up to 2 years 2 years
Secondary Response rate CT scan will be evaluated every 2 cycles (per 8 weeks)till progression. Response rate will be evaluated by RECIST criteria 8 weeks
Secondary Number of participants with treatment-related adverse events as assessed by CTCAE v3.0 through study completion, an average of 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT04973683 - AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer Phase 1
Completed NCT01417143 - Dovitinib in Adenoid Cystic Carcinoma Phase 2
Recruiting NCT04140526 - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Phase 1/Phase 2
Active, not recruiting NCT05010629 - 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma Phase 2
Recruiting NCT04801264 - Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617 Early Phase 1
Completed NCT03319641 - PSMA-PET Imaging for Advanced ACC/SDC N/A
Recruiting NCT02942693 - Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma Phase 2
Completed NCT00581360 - Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck Phase 2
Not yet recruiting NCT05553782 - Drug Screening Using Novel IMD in ACC and Salivary Cancers Early Phase 1
Completed NCT04291300 - Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients Phase 2
Active, not recruiting NCT02780310 - Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma Phase 2
Completed NCT04119453 - A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC) Phase 2
Active, not recruiting NCT02098538 - Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Phase 2
Completed NCT01558661 - Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Phase 2
Completed NCT01524692 - Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma Phase 2
Recruiting NCT03556228 - Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma Phase 1
Not yet recruiting NCT06462183 - Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC) Phase 1
Recruiting NCT01192087 - Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy Phase 1/Phase 2
Recruiting NCT04209660 - Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers Phase 2
Recruiting NCT05774899 - CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC Phase 1/Phase 2